Richa Agrawal’s Post

🔬 Exciting News in Oncology! 🔬   #Novartis announced an exclusive strategic partnership with #Arvinas to advance an #oralproteindegrader for #prostatecancer. Under the Arvinas deal, Novartis is putting up $150 million in aggregate upfront payments and pledging up to $1.01 billion in development, regulatory, and commercial milestones, plus tiered royalties.   Novartis will gain access to ARV-766, a best-in-class oral degrader for metastatic castration-resistant prostate cancer and lead the worldwide clinical development and commercialization of ARV-766 and Arvinas' preclinical AR-V7 program in #mCRPC. This partnership validates Arvinas' technology platform and demonstrates Novartis' commitment to advancing #proteindegradertechnology.   Meanwhile, Novartis' tender offer for its $2.9 billion acquisition of #MorphoSys has commenced. MorphoSys has until May 13, 2024, to accept the offer, which depends on conditions including a minimum acceptance threshold of 65%. The acquisition will strengthen Novartis' cancer franchise and expand its portfolio. #ProteinDegradation #ProstateCancer #Oncology #PharmaDeal #Partnership Novartis Arvinas MorphoSys   Detailed News: https://lnkd.in/dQ4t22j8   Follow our page for more industry updates: https://lnkd.in/de5zNWmK

A strategic partnership between Novartis and Arvinas for the development and commercialization of PROTAC androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. Here's a brief summary of the deal: 1. Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas’ preclinical AR-V7 program, with the potential under the License Agreement for up to $1.01 billion in development, regulatory, and commercial milestones, as well as tiered royalties  2. Novartis to be responsible for worldwide clinical development and commercialization of ARV-766 3. Partnership expected to accelerate and broaden the development of ARV-766 as a potential first-in-class treatment option for patients with prostate cancer Follow RAS LifeScience Solutions for more such interesting news! #oncology #raslss #developmentandcommercialization #pharmadeal #collaboration #pharmanews #pharmaindustry #

Novartis Inks $1B Protein Degrader Deal with Arvinas, Begins MorphoSys Tender Offer Under the Arvinas deal, Novartis is putting up $150 million in aggregate upfront payments and is pledging up to $1.01 billion in development, regulatory and commercial milestones, plus tiered royalties. In return, the pharma will gain access to Arvinas’ second-generation androgen receptor (AR) degrader ARV-766, which is currently being assessed in a Phase I/II study in patients with metastatic castration-resistant prostate cancer (mCRPC). The candidate, which has best-in-class potential for this indication, is designed to be orally bioavailable and in preclinical studies has demonstrated activity against tumors with both wild-type and mutated AR. Under the agreement, Novartis will now take charge of the worldwide clinical development and commercialization of ARV-766. The deal also covers the sale of Arvinas’ preclinical AR-V7 program in mCRPC, which is a next-generation protein degrader targeting both the full-length.

Just came across this groundbreaking study from Genentech on Antibody-Drug Conjugates (ADCs) and I couldn't wait to share it with you all! 🎯 ADCs represent a revolutionary approach in cancer therapy, combining the precision of monoclonal antibodies with the potent attack of small molecule drugs. But, the journey hasn't been easy. The complexity of ADCs poses unique challenges, especially in ensuring the stability and effectiveness of the small molecule component. 🧬💊 Enter the game-changer: A fully automated workflow for in-situ profiling of these small molecule drugs on ADCs. This method uses an innovative online deconjugation process integrated with two-dimensional liquid chromatography (2D-LC) and mass spectrometry. What's impressive is how this setup avoids the tedious and error-prone manual sample preparation, leading to more consistent and accurate results. 🤖🔬 This approach isn't just about efficiency; it's a significant stride in understanding the pharmacokinetics and dynamics of ADCs. With enhanced specificity, sensitivity, and precision, this method opens new doors for formulating more effective and safer cancer treatments. 🚪✨ It's amazing to see how technology and innovation are paving the way for better cancer treatments. Kudos to the brilliant minds behind this research! Let's keep pushing the boundaries of medical science. 💪🧠 🔗 Link to the publication: https://lnkd.in/eH3m-ZkT #CancerResearch #Innovation #MedicalScience #Pharmacology #ADCs #Breakthrough Rekha Thomas Dong Song Tony Pourmohamad Kenji Kurita Steven Chin Lu Dai Alexandre Goyon Colin Medley Jason Gruenhagen Tao Chen

#China based innovation in novel modalities for cancer treatment brings another uniquely functioning molecule to the forefront with just published announcement by #Zymeworks of China #NMPA acceptance of #BLA for #Zanidatamab for second-line treatment of #HER-2 positive biliary tract cancer (BTC) -https://lnkd.in/eV89W6hh. Interesting to note is that first company move was in the US so this submission is following submission to #FDA resulting in received priority review targeted for November 29, 2024. #Zanidatamab is an anti-HER2 IgG1 bispecific, biparatopic antibody (Ab), with unique and enhanced functionalities compared to both #Trastuzumab and the combination of #Trastuzumab plus #Pertuzumab . Zanidatamab binds adjacent HER2 molecules, initiates distinct HER2 reorganization and elicit potent complement-dependent cytotoxicity against high HER2-expressing tumor cells (not observed with Trastuzumab or Trastuzumab + Pertuzumab).  Efficacy of Zanidatamab reported so far from the HERIZON-BTC-01 (NCT04466891, CTR20202607) trial seems very good and supported BLAs. In previously treated patients with unresectable, locally advanced, or metastatic HER2-positive BTC Zanidatamab demonstrated the objective response rate (ORR), median duration of response (DOR), and median progression-free survival (PFS) assessed by independent central review (ICR) of 41.3% (95% CI: 30.4–52.8), 12.9 months (95% CI: 6.0–not estimable), and 5.5 months (95% CI: 3.7–7.2), respectively. This is indeed good news for biliary tract cancer (BTC) patients that have HER-2 expressing tumor and if positive opinion by regulators is reached than HER-2 testing will be critical to support delivery of the Zanidatamab benefit at the beadside. #biliary tract cancer #FDA #BLA #bispecific Ab #biparatopic Ab #China #Biotech #NMPA #HER-2 #clinical oncology

Boehringer Ingelheim Initiates Pivotal Trial for Liposarcoma Drug Boehringer Ingelheim has commenced a registration trial for brigimadlin, an investigational therapy targeting dedifferentiated liposarcoma (DDLPS), a challenging cancer type. The drug aims to restore the function of p53, a gene frequently mutated in cancer, by blocking the interaction between p53 and MDM2. Previous attempts to target mutant p53 faced challenges, making this trial a significant milestone. The BRIGHTLINE-1 study compares brigimadlin with chemotherapy in advanced DDLPS patients. Early-stage testing showed promise in slowing tumor growth. Boehringer is also advancing other cancer therapies and reported positive sales growth. Stay tuned for updates on this potential breakthrough in cancer treatment. If you're interested in continuing to read the full story, visit pharmtales, a reliable source for the most recent news in the pharmaceutical industry.  #boehringeringelheim #pharmaceuticalcompanies #pharma #pharmaceutical #pharmatles #latestnews #pharmanews #pharmaceuticalindustry #clinicaltrials https://lnkd.in/dUJN7m6R

Novartis has announced its plans to enhance its oncology pipeline by acquiring MorphoSys for €68 per share or a total of €2.7 billion in cash. This strategic move aims to bolster Novartis' position in the field of cancer treatment, particularly in the development of innovative therapies. MorphoSys brings valuable assets to Novartis, including its proprietary technology and a promising pipeline of cancer drugs, such as #tafasitamab, which is already approved for certain indications. A significant step towards expanding its portfolio of cancer treatments and addressing unmet medical needs. The deal is subject to regulatory approvals and other customary closing conditions, but once completed, it is expected to strengthen Novartis' capabilities in oncology research and development, ultimately benefiting patients worldwide. #Novartis #MorphoSys #Oncology #Pharmaceuticals #Biotechnology #Acquisition #CancerTreatment #Innovation #PipelineExpansion #MedicalResearch #Healthcare #DrugDevelopment #Investment #BusinessGrowth

Johnson & Johnson to Acquire Ambrx: Advancing Next Generation #Antibody Drug Conjugates Johnson & Johnson has entered into a definitive agreement to acquire Ambrx, a clinical-stage #biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody-drug conjugates (ADCs). The all-cash merger #transaction for a total equity value of approximately €1.8 billion ($2.0 billion), or €1.75 billion ($1.9 billion) net of estimated cash acquired. Ambrx is advancing a focused portfolio of #clinical and #preclinical programs designed to optimize the efficacy and safety of its candidate #therapeutics in multiple cancer indications. Yusri Elsayed, MD, MHSc,PhD, Global Therapeutic Area Head, #Oncology, Johnson & Johnson Innovative Medicine commented, “Ambrx’s pipeline and ADC platform present exciting future opportunities to deliver enhanced, precision biologics as we look to transform the treatment of #cancer and improve patients’ lives.” The planned acquisition presents a distinct opportunity for Johnson & Johnson to design, develop, and commercialize targeted oncology therapeutics. Ambrx’s proprietary ADC technology incorporates the advantages of highly specific targeting monoclonal antibodies securely linked to a potent #chemotherapeutic payload to achieve targeted and efficient elimination of cancer cells without the prevalent side effects typically associated with #chemotherapy. Read more on #CMI online: https://lnkd.in/ePpi24Uj

🌐 Pfizer & Nona Biosciences Forge Strategic Partnership for Advanced ADC Pfizer has inked an exclusive license deal with Nona Biosciences, a Massachusetts-based biotech, to advance the mesothelin-targeting antibody-drug conjugate (ADC) HBM9033 in treating solid tumors. 💡 Key Details: - Payment: Pfizer commits $53 million in upfront and near-term payments. - Milestones: Up to $1.05 billion pledged for specific development and commercial milestones. - Royalties: Nona eligible for tiered royalties on net sales, ranging from high-single digits to the high teens. 🎯 Focus on HBM9033: - An investigational ADC targeting the human mesothelin protein, a recognized tumor-associated antigen prevalent in solid tumors. - Demonstrated "superior potency and safety" in preclinical studies, positioning it as a potential globally best-in-class therapeutic option. 🌐 Cutting-Edge Technology: - Developed using Nona's Harbour Mice platform, leveraging proprietary transgenic mouse platforms for producing human therapeutic antibodies. - FDA clearance for Investigational New Drug application received in August 2023, marking a significant step toward clinical studies. 🤝 Strategic Significance: - Aligns with Pfizer's commitment to pioneering advancements in cancer treatment, following its recent $43 billion acquisition of ADC pioneer Seagen. 🚀 Impact and Future Prospects: - The partnership signifies a significant milestone for Harbour Mice, showcasing Nona's prowess in discovering and developing therapeutic antibodies. - Underscores Pfizer's dedication to expanding its portfolio with innovative and potent oncology solutions. Exciting times lie ahead as Pfizer and Nona embark on this collaborative journey, poised to redefine possibilities in the realm of cancer therapeutics! 🚀🩺💊 #CancerResearch #InnovationInOncology #BiotechBreakthroughs

Five months after $105M from a pre-IPO crossover round, CG Oncology is going public. #biotech #biotechnology #biotechnologie #oncology #clinicalresearch #biopharma #biopharmaceutical #biopharmaceuticals #researchanddevelopment